Lataa...
Alogliptin in combination with metformin and pioglitazone for the treatment of type 2 diabetes mellitus
Alogliptin is a selective dipeptidyl peptidase-4 inhibitor recently marketed for once-daily administration in the treatment of type 2 diabetes mellitus (T2DM). Fixed-dose combinations of alogliptin with both metformin and pioglitazone are also commercially available, providing a measure of convenien...
Tallennettuna:
| Päätekijät: | , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Dove Medical Press
2014
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4090041/ https://ncbi.nlm.nih.gov/pubmed/25050071 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DMSO.S37648 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|